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Objective: We performed a prospective randomized trial in patients with potentially
resectable stage IIIA N2 non–small cell lung cancer to confirm the efficacy of
induction chemotherapy before surgical resection.
Methods: Patients with stage IIIA N2 non–small cell lung cancer, all with histo-
logically or cytologically confirmed metastases to the ipsilateral mediastinal lymph
nodes, were randomly assigned to receive either three cycles of induction chemo-
therapy (cisplatin at 80 mg/m2 on 1 day and vindesine at 3 mg/m2 on 2 days)
followed by surgery or surgery alone.
Results: This trial was prematurely terminated because the accrual rate was too
slow, which lowered the study’s statistical power considerably. From June 1993
through April 1998, a total of 62 patients were enrolled, and 31 patients were
assigned to each treatment group. The objective clinical response rate of induction
chemotherapy was 28%. Complete resection was achieved in 20 patients in the
induction chemotherapy group (65%) and 24 in the surgery alone group (77%).
Median follow-up was 6.2 years. Median overall survivals were 17 months for the
induction group and 16 months for the surgery alone group. The estimated 1-, 3-,
and 5-year survivals, respectively, were 68% (95% confidence interval 51%-85%),
23% (95% confidence interval 8%-38%), and 10% (95% confidence interval 0%-
20%) for the induction chemotherapy group and 65% (95% confidence interval
48%-82%), 26% (95% confidence interval 11%-41%), and 22% (95% confidence
interval 7%-37%) for the surgery alone group. There was no statistically significant
difference in survival between the groups (P  .5274). Treatment-related death was
not observed in either group.
Conclusion: This randomized trial to compare induction chemotherapy (cisplatin
and vindesine) followed by surgery with surgery alone for patients with stage IIIA
N2 non–small cell lung cancer did not demonstrate a survival difference between the
groups, although this may have been because the statistical power was limited.
The treatment strategy for patients with non–small cell lung cancer(NSCLC) with ipsilateral mediastinal lymph node involvement (N2)remains controversial. Mountain1 concluded that surgical resectionwas not indicated for these patients, because most of them weresuspected to have occult distant metastasis. In Japan, however,surgical resection has been favored for these patients. Japanese
researchers reported that a considerable 5-year survival was obtained for cases with
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direct node involvement by the primary tumor or with a
limited number of N2 nodes.2,3 Clinical N2 diagnosis that
was based on plain chest radiography was reported to result
in a very low resection rate.4 Even among the patients with
resectable disease, survival was poor compared with the
patients whose N2 disease was diagnosed only by medias-
tinoscopic biopsy or by surgical dissection.3,4 Trials of
postoperative adjuvant chemotherapy for NSCLC have not
shown prognostic benefit.5-8 The Japan Clinical Oncology
Group (JCOG), performed a phase III trial that compared
surgery followed by adjuvant chemotherapy (cisplatin and
vindesine) with surgery alone for patients with completely
resected stage IIIA NSCLC.7 This trial failed to demonstrate
therapeutic benefit of the adjuvant chemotherapy. A multi-
variable analysis, however, demonstrated that pathologi-
cally staged N2 disease was a significant prognostic factor
for survival. This result indicated that patients with stage
IIIA N2 NSCLC should be studied separately from the other
patients with IIIA disease.
Although many phase II trials have suggested benefits
for induction chemotherapy or induction chemoradiother-
apy for patients with stage III N2 NSCLC,9-13 the efficacy of
these modalities is not definitively established by phase II
trials. We planned a prospective randomized trial for pa-
tients with potentially resectable stage IIIA N2 NSCLC to
compare induction chemotherapy followed by surgery with
surgery alone. This study was the first randomized trial for
this setting. We used combination chemotherapy with cis-
platin and vindesine, which was the most popular combina-
tion chemotherapy for NSCLC at that time in Japan. Al-
though this phase III trial was designed to enroll 100
patients in each group within 3 years, starting in June 1993,
it was stopped in April 1998 because the patient accrual rate
was too slow.
Patients and Methods
Patient Eligibility
Histologic or cytologic diagnosis of NSCLC was obtained by
bronchoscopic or transcutaneous needle biopsy before registration.
All patients had histologically or cytologically documented ipsi-
lateral mediastinal lymph node metastasis according to a medias-
tinoscopic specimen and were previously untreated. Preoperative
staging included chest radiography, computed tomography (CT) of
the chest, CT or ultrasonography of the upper abdomen, CT or
magnetic resonance imaging of the brain with contrast media, and
bone scintigraphy. Eligibility criteria included a leukocyte count
greater than 4000 cells/mm3, a platelet count greater than 100,000
cells/mm3, a hemoglobin count greater than 10 g/dL, and normal
renal and hepatic functions. Other criteria were as follows. (1)
Clinical N2 disease was observable on plain chest radiography or
CT. (2) Patients had to be younger than 76 years. (3) Complete
resection had to be deemed possible. (4) Performance status had to
be 0 or 1. (5) Patients had to provide written informed consent. (6)
Patients with carcinoid tumor, mucoepidermoid carcinoma, or
adenoid cystic carcinoma were excluded. (7) Patients with vena
cava syndrome, Pancoast syndrome, T3 tumor with rib involve-
ment, or paratracheal lymph node involvement in a left-sided
tumor were excluded.
This phase III protocol was inspected and approved by the
JCOG ethical committee. Patient registration was done at the
JCOG data center.
Treatment Strategy (Figure 1)
All eligible patients were randomly assigned to receive either
induction chemotherapy followed by surgery or surgery alone.
Induction chemotherapy consisted of cisplatin (80 mg/m2 given
intravenously on day 1) and vindesine (3 mg/m2 given intrave-
nously on days 1 and 8). This treatment cycle was repeated two
more times every 4 weeks for patients who had sufficiently recov-
ered from the toxic effects of the previous cycle. Adverse effects
of induction chemotherapy were recorded according to the JCOG
grade.14
Surgical resection was performed within 6 weeks after the last
chemotherapy. Surgery was either lobectomy, bilobectomy, or
pneumonectomy along with systematic mediastinal lymph node
dissection. Patients who were found to have unresectable disease at
operation or whose resection was found to be incomplete after
operation could receive radiation therapy. Patients whose resection
was complete were not allowed to undergo any adjuvant therapy.
Treatment for recurrence was not restricted.
Figure 1. Treatment schema of JCOG 9209. Induction chemotherapy of three cycles of cisplatin (P) at 80 mg/m2 on
day 1 and vindesine (V) at 3 mg/m2 on days 1 and 8.
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Statistical Methods
The number of patients to be enrolled was calculated from the lung
cancer survival data at the National Cancer Center in Japan15 and
Memorial Sloan-Kettering Cancer Center.16 Seventy-five patients
in each group were required to provide 80% power to detect a 15%
increase (25%-40%) in 3-year survival in the induction chemo-
therapy group compared with the surgery alone group (  .05
  .2). With an expected 10% drop-off among the registered
patients, a total of 165 patients would be necessary. We therefore
aimed at collecting 200 patients in 3 years. All patients randomly
assigned in this trial were followed up to date and included in the
analysis. Duration of survival or time to recurrence was calculated
from the date of random assignment until the date of death,
recurrence, or the last follow-up. The probabilities of overall
survival and disease-free survival were calculated with the Kaplan-
Meier method. The log-rank test was used to compare survival
curves. Statistical differences between proportions were calculated
by 2 test. All calculations were performed with the StatView
(version 5.0; SAS Institute Inc, Cary, NC) software package.
Results
Patient Characteristics
Because the patient accrual rate was too slow, despite the
original aim of 200 patients within 3 years, this study was
prematurely terminated in almost 5 years. A total of 62
patients were enrolled at 18 JCOG institutions from June
1993 through April 1998. Thirty-one patients were ran-
domly allocated to each treatment group. There were no
significant differences between the two groups in age, sex,
and histologic distribution (Table 1). There were more pa-
tients with clinically staged T1 disease in the surgery alone
group than in the induction chemotherapy group.
Induction Chemotherapy
Twenty-two (71%) of 31 patients undergoing chemotherapy
received three full-dose cycles of induction chemotherapy
(Table 2). The objective response rate was 28% (Table 3).
Seven of 8 patients with a partial response underwent three
full cycles. Another patient with a partial response received
two cycles. Severe toxicity (grade 4) was not observed.
Grade 3 toxicities were leukocytopenia in 31%, anemia in
14%, and vomiting in 14%. Three (10%) patients of 31 did
not undergo operation because distant metastasis developed
in the bone, brain, and contralateral lymph node.
Surgery and Pathologic Examination
Complete resection was achieved in 20 patients (65%) in the
induction group and in 24 patients (77%) in the surgery
alone group (Table 4). Exploratory thoracotomy was done
TABLE 1. Patient characteristics
Induction
chemotherapy Surgery p value
No. of patients 31 31
Age (y) 59 (32-74) 61 (45-74) .3757
Sex (No.) .7884
Men 20 21
Women 11 10
Histologic type (No.) .8339
Adenocarcinoma 21 20
Squamous cell carcinoma 7 8
Others 3 3
Clinical T stage (No.) .0327
T1 2 11
T2 25 17
T3 3 3
Unknown 1 0
TABLE 2. Induction chemotherapy
Performed
cycles Patients Reason for halting
Progressive
disease
Patient
refusal
0 2 1 1
1 3 2 1
2 4 3 1
3 22 (71%)
All figures represent numbers of patients.
TABLE 3. Clinical response to induction chemotherapy
(n  29)
No. %
Complete response 0 0
Partial response 8 28
Stable disease 12 41
Progressive disease 9 31
TABLE 4. Operations
Operation
Induction
chemotherapy
(n  31)
Surgery
(n  31)
R0 20 24
Pneumonectomy 2 4
Lobectomy 18 20
R1 1 3
Pneumonectomy 0 1
Lobectomy 1 2
R2 2 2
Pneumonectomy 0 0
Lobectomy 2 2
Exploratory thoracotomy 5 2
Not indicated 3
All figures represent numbers of patients. A complete resection (R0) was
defined as pathologic demonstration of negative tissue margin and an
assessment by the surgeon that all detectable disease had been removed.
Patients who had a complete gross resection in whom positive margins
were found on final pathologic review were classified as having under-
gone microscopically incomplete resection (R1). Gross residual disease
after attempted resection was classified as R2.
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in 5 of the induction group (19%) and 2 of the surgery alone
group (6%). Pleural dissemination and intrapulmonary me-
tastases were detected in 3 patients each. The other patient
had balky mediastinal node swelling. Complete disappear-
ance of primary tumor in resected specimen occurred in no
patients. Four patients had no residual tumor in resected
mediastinal lymph nodes according to histologic study, but
1 of them had residual tumor in a hilar lymph node.
Survival Analysis
Median follow-up was 6.2 years (range 3.4-7.8 years). No
patient died within 30 days after the operation. Treatment-
related death was not observed in either group. Median
overall survivals were 17 months for the induction chemo-
therapy group and 16 months for the surgery alone group.
The estimated 1-, 3-, and 5-year survivals, respectively,
were 68% (95% confidence interval [CI] 51%-85%), 23%
(95% CI 8%-38%), and 10% (95% CI 0%-20%) for the
induction group and 65% (95% CI 48%-82%), 26% (95%
CI 11%-41%), and 22% (95% CI 7%-37%) for the surgery
alone group (Figure 2). There was no statistically significant
difference in survival between the groups (P  .5274).
When only patients with completely resected disease were
compared, the median survival and estimated 1-, 3- and
5-year survivals, respectively, were 18 months, 80% (95%
CI 63%-97%), 25% (95% CI 6%-44%), and 10% (95% CI
0%-23%) for the induction group and 18 months, 63% (95%
CI 44%-82%), 33% (95% CI 14%-52%), and 29% (95% CI
12%-47%) for the surgery alone group (P  .6066). Ac-
cording to induction chemotherapy response, the median
survival and estimated 3-year survival, respectively, were
30 months and 38% (95% CI 4%-72%) in patients with a
partial response, 18 months and 18% (95% CI 0%-41%) in
patients with stable disease, and 12 months and 10% (95%
CI 0%-29%) in patients with progressive disease. Statisti-
cally significant difference in survival was not observed
(partial response vs stable disease P  .5044, partial re-
sponse vs progressive disease P  .0512, stable disease
versus progressive disease P  .2304). When estimated 1-,
3-, and 5-year disease-free survivals, respectively, were
compared (Figure 3), they were 57% (95% CI 37%-77%),
10% (95% CI 0%-23%), and 10% (95% CI 0%-23%) for the
induction group and 38% (95% CI 20%-56%), 27% (95%
CI 11%-43%), and 21% (95% CI 5%-37%) for the surgery
alone group (P  .5964).
Discussion
Long-term survival after surgical resection of patients with
locally advanced NSCLC is poor, especially for those with
N2 disease.3,4,17,18 The JCOG conducted a phase III trial to
compare surgery followed by adjuvant chemotherapy with
surgery alone for completely resected stage IIIA NSCLC.
This trial failed to demonstrate any therapeutic benefit of
adjuvant chemotherapy.7 The PORT Meta-analysis Trial-
ists19 reported that the efficacy of postoperative radiation
therapy was not supported. To date postoperative adjuvant
therapy has not been proved effective.
Three randomized trials that compared induction chemo-
therapy followed by surgery with surgery alone or surgery
followed by radiation (by Pass and colleagues,20 Rosell and
associates21,22 and Roth and coworkers23,24) showed signif-
icant or marginal survival benefit of induction chemother-
apy patients with stage IIIA NSCLC (Table 5). These re-
Figure 2. Overall Kaplan-Meier survivals in months after random assignment.
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ports revealed high clinical response rates (35%-62%)
among patients receiving induction chemotherapy. How-
ever, these three trials used different treatment strategies,
and Rosell and associates’ and Roth and coworkers’ study
populations included patients with N0 and N1 disease.21-24
We planned to study induction therapy efficacy in the more
homogeneous cohort of patients with potentially resectable
stage IIIA N2 NSCLC and performed a prospective ran-
domized trial to compare induction chemotherapy followed
by surgery with surgery alone.
Although this trial was designed to enroll 100 patients in
each group within 3 years, the recruitment was too slow and
the trial was discontinued, resulting in a total of only 62
patients in almost 5 yeas. Sixty-two patients (31 patients in
each group) is calculated to provide 24% power to detect a
15% increase in 3-year survival in the induction chemother-
apy group (  .05,   .76). The possibility of a type II
error is so high that it may invalidate our data. The greatest
contributor to the slow rate was failure to obtain informed
consent. The reasons for consent refusal were the lack of
rewarding compensation to the patients, prolonged hospi-
talization in the induction chemotherapy group, and wide
reports in the domestic media of the ineffectiveness of
chemotherapy for NSCLC. Under the circumstances this
trial was prematurely terminated in April 1998.
Unlike previous induction chemotherapy studies, our
Figure 3. Disease-free Kaplan-Meier survivals in months after random assignment.
TABLE 5. Reported phase III trials, with or without induction therapy, in other studies of patients with stage IIIA NSCLC
and our own
Reference Stage Therapy Patients MST (m) P value
Pass and colleagues20 IIIA (N2) Preoperative and postoperative
etoposide and cisplatin
13 29 .095
Postoperative radiotherapy 14 16
Rosell and associates21,22 IIIA Preoperative and postoperative
cisplatin, ifosfamide, and
mitomycin
30 22 .005
Postoperative radiotherapy 30 10
Roth and coworkers23,24 IIIA Preoperative and postoperative
cyclophosphamide, etoposide,
and cisplatin
28 21 .056
Surgery alone 32 14
Current data IIIA (N2) Preoperative vindesine and
cisplatin
31 17 .527
Surgery alone 31 16
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trial population showed poor response to induction chemo-
therapy (complete resection rate 0%, partial response rate
28%), and no survival difference was observed between
induction and surgery alone groups. We think that this was
because all our eligible patients had N2 disease, unlike
previous studies that included patients with N0 or N1 dis-
ease.
Chemotherapy regimens with new agents, including pac-
litaxel, docetaxel, vinorelbine, and gemcitabine, have re-
cently been reported to be effective for advanced NSCLC
with fewer, less severe effects.25-29 Sandler and associates26
reported that as the first-line treatment for NSCLC the
regimen of gemcitabine plus cisplatin was superior to cis-
platin alone in terms of response rate, time to disease
progression, and overall survival. Comella and associates27
reported that a cisplatin, gemcitabine, and vinorelbine reg-
imen was associated with a substantial survival gain when
compared with a cisplatin and vinorelbine combination for
advanced NSCLC. Although a survival benefit conferred by
induction chemotherapy before surgical resection for stage
IIIA N2 NSCLC was not demonstrated in our trial, these
new agent combinations may prove beneficial for locally
advanced NSCLC in future trials.
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Appendix
The study was carried out as a trial by the Lung Cancer Surgical
Study Group of the Japan Clinical Oncology Group, chairperson
Professor Harubumi Kato, Tokyo Medical University.
The cases in this study were collected from the National Cancer
Center Hospital East (Kanji Nagai); National Cancer Center Hos-
pital (Ryosuke Tsuchiya); National Kinki Chuo Hospital (Takashi
Mori); Osaka City General Hospital (Hiroto Tada); National Ky-
ushu Cancer Center (Yukito Ichinose); Niigata Cancer Center
Hospital (Teruaki Koike); Toho University School of Medicine
(Keigo Takagi); Yokohama Municipal Citizen’s Hospital (Masa-
hiro Kase); Institute of Aging, Development, and Cancer, Tohoku
University (Takashi Kondo); Kanagawa Cancer Center Hospital
(Haruhiko Nakayama); Tochigi Cancer Center (Kohei Yokoi);
Osaka Prefectural Habikino Hospital (Tsutomu Yasumitsu);
Yamagata Prefectural Central Hospital (Toru Sato); National De-
fense Medical College (Yuichi Ozeki); Toyama Prefectural Cen-
tral Hospital (Hideki Miyazawa); National Toneyama Hospital
(Osamu Kuwabara); National Kure Hospital (Kenji Nakamura);
and Shikoku Cancer Center Hospital (Hideyuki Saeki).
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